Myriapod NGS Dry line includes NGS panels for DNA and RNA sequencing dedicated to the study of predictive- diagnostic SNV (SNP, In/del, fusions) clinically relevant in the most frequent cancer types as: colon, lung, melanoma, central nervous system, GIST, thyroid, and bladder, and also independent tissue biomarkers, like NTRK 1, 2 and 3 gene fusions.

Main features:

  • Ready to use: Dry, ready-to-use, in pre-aliquoted strip reagent format
  • Simple: the easiest and fastest workflow on the market for NGS libraries preparation, with a hands-on time < 2 hours and a turnaround time, from sample to sequencing, of 8 hours.
  • Flexible: optimized on Illumina® Miseq™, MiniSeq™ and iSeql100™ with the flexibility to test from 2 to 46 samples/run.
  • Low amount and quality of input: validated to work from 10 ng/reactions of DNA and RNA extracted from FFPE or cfDNA.
  • Certified: fully CE-IVD protocol, from sample to result with data processing through Myriapod® NGS Data Analysis Software, fully automatic, bioinformatic analysis local system without any needs to send out data or use cloud based solutions.

Myriapod® NGS data Analysis: the CE-IVD solution for local NGS data analysis

Myriapod® NGS Data Analysis is a complete, in vitro diagnostic and easy-to-use bioinformatics solution, which come with the Myriapod® NGS Data Analysis Software and its own dedicated workstation. Myriapod NGS solution provides simplicity in the analysis for fast and easy reporting. Further, the data management system offers the highest level of security with a completely localized data analysis, so sensitive data is not sent over the network or to a cloud system. Myriapod NGS Data Analysis solution complies with all the EU General Data Protection Regulations (GDPR).

Principle of the method: the Myriapod® NGS Cancer panel DNA kit allows the preparation of Next Generation Sequencing (NGS) libraries compatible with the Illumina “MiSeq®”, “MiniSeq™” and “iSeq™ 100” platforms for the identification of SNV and indels in 16 clinical diagnostic genes.

Source material: genomic DNA, purified and non-purified, isolated from tumour tissue (fresh, frozen, formalin-fixed including paraffin (FFPE)) or Plasma (cfDNA); extraction reagents included in the kit for DNA extraction from FFPE samples can be used.

Intended Use: CE IVD workflow from extraction to bionformatics analysis of 17 genes whose alterations are implicated in numerous tumour types.

Genes included in the panel:

Principle of the method: The Myriapod NGS Cancer panel RNA” kit allows the preparation of Next Generation Sequencing (NGS) libraries compatible with the Illumina “MiSeq”, “MiniSeq™” and “iSeq™ 100” platforms for the identification of more than 1000 fusion events in 10 clinical diagnostic genes.

Source material: RNA isolated from tumor tissue (fresh, frozen, formalin-fixed including paraffin (FFPE)) or from needle-asporates (FNA).

Intended use: CE IVD workflow from extraction to bioinformatics for the study of 10 gene fusions of predictive-diagnostic interest for lung tumors (ROS1, RET, ALK, MET), thyroid (RET, ALK, PPARG), bladder (FGFR2, FGFR3), cholangiocarcinoma (FGFR2) and agnostic markers (non-specific tissue) NTRK1, NTRK2, NTRK3.

Genes included in the panel:

Principle of the method: The Myriapod® NGS BRCA 1-2 Cancer panel kit through two multiplex PCR reactions allows the preparation of Next Generation Sequencing (NGS) libraries compatible with Miseq, iSeq 100 and MiniSeq platforms including the entire coding sequence, exon-intron junctions (at least 10 bases flanking) and partially the 5′ and 3′ UTR regions of BRCA1 and BRCA2 genes.

Starting material: Genomic DNA, isolated from whole blood in EDTA and from formalin-fixed paraffin-embedded tumor tissue (FFPE).

Intended use: Myriapod NGS BRCA 1-2 panel® is an in vitro diagnostic assay for the identification of single nucleotide polymorphisms (SNVs), insertion-deletions (indels) and copy number variations (CNVs) of the BRCA1 and BRCA2 genes.

Enter your information below to download the brochure

    I confirm that I have read the information on the personal data management.

    I agree to the processing of my personal data according to the above mentioned information

    *Both options must be selected to proceed with the download

    Outsourcing of data and sample analysis do not eliminate the legal responsibility of the laboratory in the processing of personal data, even if protected by complex contracts subscribed with the service provider and even if the last one is certified according to a standard for “Information Security Management” (eg. ISO 27001).

    Learn more by downloading the flyer

    Category

    Next Generation Sequencing

    Validated tools
    MiSeq Illumina
    MiniSeq Illumina
    iSeq100 Illumina
    Related publications
    Request information

      Please insert your email address below, we will contact you soon.

      I confirm that I have read the information on the personal data management.

      I agree to the processing of my personal data
      according to the above mentioned information

      *Both options must be selected